Loading...
IVCR.Q logo

Invacare CorporationOTCPK:IVCR.Q Aktienübersicht

Marktkapitalisierung US$512.8k
Aktienkurs
n/a
Mein Marktwert
n/v
1Y-99.1%
7D-10.6%
1D
Wert des Portfolios
​
Siehe

Invacare Corporation

OTCPK:IVCR.Q Lagerbericht

Marktkapitalisierung: US$512.8k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Invacare (IVCR.Q) Aktienübersicht

Invacare Corporation, together with its subsidiaries, designs, manufactures, distributes, and exports medical equipment for use in home health care, retail, and extended care markets worldwide. Mehr Details

IVCR.Q grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung2/6
Künftiges Wachstum0/6
Vergangene Leistung0/6
Finanzielle Gesundheit1/6
Dividenden0/6

Risikoanalyse

Die Erträge sind in den letzten 5 Jahren um 2.6% pro Jahr zurückgegangen

Hat keine nennenswerte Marktkapitalisierung ($513K)

Sehr volatiler Aktienkurs in den letzten 3 Monaten im Vergleich zum US -Markt

Hat weniger als 1 Jahr Cash Runway

+ 1 mehr Risiko

IVCR.Q Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Invacare Corporation Wettbewerber

Preisentwicklung & Leistung

Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für Invacare
Historische Aktienkurse
Aktueller AktienkursUS$0.013
52-Wochen-HochUS$1.64
52-Wochen-TiefUS$0.011
Beta0.51
1 Monat Veränderung-10.00%
3 Monate Veränderung-62.60%
1 Jahr Veränderung-99.09%
3 Jahre Veränderung-99.77%
5 Jahre Veränderung-99.92%
Veränderung seit IPO-99.49%

Aktuelle Nachrichten und Updates

Recent updates

Seeking Alpha • Feb 01

Invacare falls on bankruptcy filing

Medical equipment maker Invacare Corporation (NYSE:IVC) lost ~20% in the pre-market trading Wednesday after announcing that the company and two U.S.-based subsidiaries filed for voluntary Chapter 11 bankruptcy. The cases, filed in the Bankruptcy Court for the Southern District of Texas, do not include its international operations and are not expected to impact the company’s ability to serve its global clientele, Invacare (IVC) said. The bankruptcy cases follow a financial restructuring agreement the company inked with almost all of its debt holders and most of the convertible noteholders. The deal, known as Restructuring Support Agreement, allows Invacare (IVC) to reduce its debt by ~$240M and provides the company with $60M equity capital to repay certain debt and fund its transformation plan. “The company expects to emerge with significantly less debt on its balance sheet and will secure additional liquidity to support long-term growth,” Invacare’s (IVC) recently appointed Chief Executive Geoff Purtill noted.
Seeking Alpha • Dec 27

Invacare announces additional draw of $5.5M term loans

Invacare (NYSE:IVC) announced additional draw of $5.5M of term loans under its credit agreement. The company said certain funds will be managed by Highbridge Capital Managed. The company will use the proceeds of the additional draw for general corporate purposes, it said. About $14M of additional liquidity remains available under the Amended Highbridge Credit Agreement, subject to satisfaction of certain conditions set forth therein.
Analyseartikel • Nov 14

Invacare Corporation (NYSE:IVC) Analysts Just Slashed Next Year's Estimates

Market forces rained on the parade of Invacare Corporation ( NYSE:IVC ) shareholders today, when the analysts...
Seeking Alpha • Nov 07

Invacare GAAP EPS of -$0.92, revenue of $170.4M

Invacare press release (NYSE:IVC): Q3 GAAP EPS of -$0.92. Revenue of $170.4M (-24.0% Y/Y). Gross margin was 18.4%, a decrease of 850 basis points, including 510 basis points of decline related to the write-down of respiratory inventory as a result of the decision to discontinue production of respiratory products. SG&A expense decreased 1.4% to $55.4 million, and constant currency SG&A increased 4.5%. Operating loss was $33.4 million compared to a loss of $24.8 million. Adjusted EBITDA loss was $11.8 million, compared to positive $8.0 million. Free cash flow usage was $20.5 million compared to usage of $6.1 million.
Seeking Alpha • Sep 29

Invacare receives non-compliance letter from NYSE

Invacare (NYSE:IVC) said on Thursday it had received notice from the New York Stock Exchange that it was not in compliance with the NYSE listed company manual as the average closing price was less than $1 per share over a consecutive 30 trading-day period. The company plans to notify the NYSE by October 7 on its plan to return to compliance with the NYSE continued listing standard. The company can regain compliance at any time within the six-month period. The company is required to have a closing share price of at least $1 over a consecutive 30 trading-day period. The company intends to consider available alternatives, including, but not limited to, a reverse stock split, subject to shareholder approval no later than at the company’s next annual meeting of shareholders.
Seeking Alpha • Aug 29

Invacare names Geoffrey Purtill as interim president and executive chief

Invacare (NYSE:IVC) on Monday has named Geoffrey P. Purtill as the company's interim president and chief executive officer, succeeding departing chairman, president and CEO Matthew E. Monaghan. The transition is effective Aug. 28, 2022. Geoffrey P. Purtill had been serving as the Invacare's senior vice president and general manager, EMEA and APAC.  "We welcome Geoff who has distinguished himself throughout his tenure with Invacare. The Board has full confidence that he has the right skillset and industry experience to lead the company through this transition as we search for a permanent successor who can accelerate the achievement of our objectives," said Cliff Nastas, Invacare’s lead independent director. In addition, the Board has announced the appointment of Michael J. Merriman as its director and non-executive Chairman. Merriman previously served as chair of the company's audit committee from 2014 to 2018. "As the independent Chairman of the Board, Merriman succeeds Cliff Nastas as the company's lead independent director," report.  IVC stock jumps 9% in premarket on Monday to trade at $0.94 vs 52-week level of $0.80 to $8.73.
Seeking Alpha • Aug 23

Invacare adds two new directors after deal with largest investor Azurite

Medical equipment maker Invacare Corporation (NYSE:IVC) has appointed two new directors with immediate effect as part of a corporation agreement with its largest shareholder, Azurite Management LLC, which owns more than 10% of IVC stock. The new directors, Steven H. Rosen and Edward F. Crawford will replace Julie A. Beck and Stephanie L. Fehr, who resigned from the board on Aug. 22. Mr. Rosen is the Co-Founder, and Co-Chief Executive of Ohio-based private equity firm Resilience Capital Partners LLC. Crawford, a former U.S. ambassador to Ireland from 2019 to 2021, currently serves Resilience as a Member of its Board of Advisors. As part of the deal, IVC has agreed to set up a five-member Strategy and Operational Improvement Committee comprising the new appointees. The terms of the corporation agreement include certain standstill provisions which, among other things, will bar Azurite from raising its IVC stake above 19.9%.
Analyseartikel • Apr 30

Returns Are Gaining Momentum At Invacare (NYSE:IVC)

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Analyseartikel • Jan 27

Invacare (NYSE:IVC) Use Of Debt Could Be Considered Risky

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analyseartikel • Dec 01

Returns On Capital Are Showing Encouraging Signs At Invacare (NYSE:IVC)

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Analyseartikel • Sep 30

Here's Why Invacare (NYSE:IVC) Is Weighed Down By Its Debt Load

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analyseartikel • Aug 06

When Should You Buy Invacare Corporation (NYSE:IVC)?

Invacare Corporation ( NYSE:IVC ), might not be a large cap stock, but it saw a decent share price growth in the teens...
Analyseartikel • May 14

Increases to CEO Compensation Might Be Put On Hold For Now at Invacare Corporation (NYSE:IVC)

In the past three years, the share price of Invacare Corporation ( NYSE:IVC ) has struggled to grow and now...
Analyseartikel • May 03

Returns On Capital Are Showing Encouraging Signs At Invacare (NYSE:IVC)

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Analyseartikel • Mar 03

Invacare Corporation's (NYSE:IVC) Path To Profitability

We feel now is a pretty good time to analyse Invacare Corporation's ( NYSE:IVC ) business as it appears the company may...
Analyseartikel • Feb 05

Invacare (NYSE:IVC) Has A Somewhat Strained Balance Sheet

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Analyseartikel • Jan 10

What Can The Trends At Invacare (NYSE:IVC) Tell Us About Their Returns?

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Analyseartikel • Dec 14

Invacare's(NYSE:IVC) Share Price Is Down 48% Over The Past Five Years.

It is a pleasure to report that the Invacare Corporation ( NYSE:IVC ) is up 33% in the last quarter. But over the last...
Analyseartikel • Nov 23

Invacare Corporation's (NYSE:IVC) Shift From Loss To Profit

With the business potentially at an important milestone, we thought we'd take a closer look at Invacare Corporation's...

Aktionärsrenditen

IVCR.QUS Medical EquipmentUS Markt
7D-10.6%-2.5%2.0%
1Y-99.1%-21.4%23.3%

Rendite im Vergleich zur Industrie: IVCR.Q unter dem Niveau der Branche US Medical Equipment , die im vergangenen Jahr eine Rendite von -21.4% erzielte.

Rendite vs. Markt: IVCR.Q hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 23.3 erzielte.

Preisvolatilität

Is IVCR.Q's price volatile compared to industry and market?
IVCR.Q volatility
IVCR.Q Average Weekly Movement28.2%
Medical Equipment Industry Average Movement8.6%
Market Average Movement7.2%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stabiler Aktienkurs: Der Aktienkurs von IVCR.Q war in den letzten 3 Monaten im Vergleich zum US -Markt volatil.

Volatilität im Zeitverlauf: IVCR.QDie wöchentliche Volatilität (28%) war im vergangenen Jahr stabil, liegt aber immer noch höher als bei 75 % der US Aktien.

Über das Unternehmen

GegründetMitarbeiterCEOWebsite
18852,800Geoff Purtillwww.invacare.com

Invacare Corporation's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Invacare im Vergleich zum Marktanteil des Unternehmens?
IVCR.Q grundlegende Statistiken
MarktanteilUS$512.81k
Gewinn(TTM)-US$101.07m
Umsatz(TTM)US$741.73m
0.0x
Kurs-Umsatz-Verhältnis
0.0x
Kurs-Gewinn-Verhältnis

Ist IVCR.Q zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
IVCR.Q Gewinn- und Verlustrechnung (TTM)
EinnahmenUS$741.73m
Kosten der EinnahmenUS$557.69m
BruttogewinnUS$184.04m
Sonstige AusgabenUS$285.12m
Gewinn-US$101.07m

Zuletzt gemeldete Gewinne

Dec 31, 2022

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)-2.66
Bruttomarge24.81%
Nettogewinnspanne-13.63%
Schulden/Eigenkapital-Verhältnis436.8%

Wie hat sich IVCR.Q auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2023/05/05 02:04
Aktienkurs zum Tagesende2023/05/05 00:00
Gewinne2022/12/31
Jährliche Einnahmen2022/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Invacare Corporation wird von 7 Analysten beobachtet. dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Robert LabickCJS Securities, Inc.
Constantine DavidesD. Boral Capital LLC.
Matthew MishanKeyBanc Capital Markets Inc.